Table 3 Characteristics and data of low-risk patients in the initial treatment (IVIG)-responsive and initial treatment-resistant groups

number

116

28

Age in month

29.5 [4–130]

22 [4–107]

0.352

Male gender, n (%)

56 (48.3)

13 (46.4)

0.861

Illness day at diagnosis

5 [2–10]

5 [3–8]

0.436

Kobayashi score

2 [0–4]

3 [0–4]

0.030

TN-C, ng/mL

106.6 [29.1–449.6]

113.5 [46.6–483.4]

0.432

WBC, × 10³/μL

13.0 [6.1–32.3]

12.7 [6.3–22.0]

0.435

Neutrophil, %

66 [24–91]

67 [26–88]

0.418

Platelet, ×10⁴/mL

33.3 [16.6–53.3]

32.9 [19.4–62.5]

0.612

CRP, mg/dL

6.7 [1.3–31.4]

8.8 [1.5–20.0]

0.190

Albumin, g/dL

3.6 [2.6–4.8]

n = 115

3.6 [2.6–4.3]

0.998

T-bilirubin, mg/dL

0.5 [0.1–3.1]

n = 114

0.6 [0.2–3.4]

0.064

AST, IU/L

34 [15–298]

33 [18–236]

0.677

ALT, IU/L

19 [5–442]

24 [8–237]

0.608

Sodium, mEq/L

136 [127–143]

135 [127–138]

0.093